[go: up one dir, main page]

MX2012006720A - Composicion farmceutica para el tratamiento de sindrome del ojo seco. - Google Patents

Composicion farmceutica para el tratamiento de sindrome del ojo seco.

Info

Publication number
MX2012006720A
MX2012006720A MX2012006720A MX2012006720A MX2012006720A MX 2012006720 A MX2012006720 A MX 2012006720A MX 2012006720 A MX2012006720 A MX 2012006720A MX 2012006720 A MX2012006720 A MX 2012006720A MX 2012006720 A MX2012006720 A MX 2012006720A
Authority
MX
Mexico
Prior art keywords
treatment
pharmaceutical composition
dry eye
eye syndrome
compositions
Prior art date
Application number
MX2012006720A
Other languages
English (en)
Inventor
Bastian Theisinger
Sonja Theisinger
Bernhard Guenther
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41731659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012006720(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of MX2012006720A publication Critical patent/MX2012006720A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona nuevas composiciones farmacéuticas para el tratamiento de la queratoconjuntivitis seca que comprenden vehículos líquidos que incluyen uno o más alcanos semifluorados. Las composiciones incorporan un ingrediente activo escogido entre el grupo de inmunosupresores de macrolida. Se pueden administrar por vía tópica al ojo. La invención además proporciona estuches que comprenden dichas composiciones.
MX2012006720A 2009-12-14 2010-12-13 Composicion farmceutica para el tratamiento de sindrome del ojo seco. MX2012006720A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09015423A EP2335735A1 (en) 2009-12-14 2009-12-14 Pharmaceutical composition for treatment of dry eye syndrome
PCT/EP2010/069495 WO2011073134A1 (en) 2009-12-14 2010-12-13 Pharmaceutical composition for treatment of dry eye syndrome

Publications (1)

Publication Number Publication Date
MX2012006720A true MX2012006720A (es) 2012-07-30

Family

ID=41731659

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006720A MX2012006720A (es) 2009-12-14 2010-12-13 Composicion farmceutica para el tratamiento de sindrome del ojo seco.

Country Status (15)

Country Link
US (1) US8614178B2 (es)
EP (2) EP2335735A1 (es)
JP (5) JP5663595B2 (es)
KR (2) KR101652714B1 (es)
CN (1) CN102652022B (es)
AU (1) AU2010333039B2 (es)
BR (3) BR122017018955B1 (es)
CA (2) CA2941956C (es)
DK (1) DK2512515T3 (es)
ES (1) ES2449308T3 (es)
IN (1) IN2012DN03128A (es)
MX (1) MX2012006720A (es)
PL (1) PL2512515T3 (es)
PT (1) PT2512515E (es)
WO (1) WO2011073134A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5695035B2 (ja) 2009-06-03 2015-04-01 フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． 前眼部薬物供給
BR112012023421B1 (pt) 2010-03-17 2021-09-14 Novaliq Gmbh Composição farmacêutica para tratamento de aumento de pressão intraocular
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
EP2714008B1 (en) 2011-05-25 2016-12-14 Novaliq GmbH Pharmaceutical composition for administration to nails
PL2714010T3 (pl) 2011-05-25 2017-08-31 Novaliq Gmbh Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach
AU2013211645B2 (en) * 2012-01-23 2017-06-15 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
CA3142049C (en) * 2012-09-12 2023-08-29 Novaliq Gmbh Semifluorinated alkane compositions
TR201812013T4 (tr) 2012-09-12 2018-09-21 Novaliq Gmbh Göz yikama bi̇leşi̇mleri̇.
CA2997744C (en) * 2012-09-12 2019-12-31 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
EP2730291A1 (en) * 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
JP6304475B2 (ja) * 2013-01-31 2018-04-04 ロート製薬株式会社 点眼剤
US20160022648A1 (en) 2013-03-13 2016-01-28 Santen Pharmaceutical Co., Ltd. Therapeutic agent for meibomian gland dysfunction
CA2918419C (en) * 2013-07-23 2022-05-03 Novaliq Gmbh Stabilized antibody compositions
CA2927321A1 (en) * 2013-10-15 2015-04-23 Forsight Vision5, Inc. Formulations and methods for increasing or reducing mucus
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
WO2016168141A1 (en) 2015-04-13 2016-10-20 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
WO2017058774A1 (en) * 2015-09-29 2017-04-06 The Regents Of The University Of California Methods of diagnosing diseases of mucosal surfaces
WO2017055454A1 (en) * 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds and their compositions
DK3356313T3 (da) * 2015-09-30 2020-07-20 Novaliq Gmbh 2-perfluorhexyloktan til oftalmisk indgivelse
JP2019520357A (ja) 2016-06-23 2019-07-18 ノバリック ゲーエムベーハー 局所投与方法
WO2018054932A1 (en) * 2016-09-22 2018-03-29 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
CN109906085B (zh) * 2016-09-23 2024-03-08 诺瓦利克有限责任公司 含有环孢素的眼用组合物
CA3036313A1 (en) * 2016-09-28 2018-04-05 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
CN110248657A (zh) * 2016-12-22 2019-09-17 诺瓦利克有限责任公司 用于治疗眼内炎性眼病的包含他克莫司的组合物
ES2965883T3 (es) * 2016-12-23 2024-04-17 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad del ojo seco
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
PL3612228T3 (pl) * 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
WO2018202835A1 (en) 2017-05-05 2018-11-08 Novaliq Gmbh Process for the production of semifluorinated alkanes
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
SG11202002640YA (en) 2017-09-27 2020-04-29 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
CA3091308A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
WO2019206956A1 (en) 2018-04-27 2019-10-31 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
US20210346313A1 (en) * 2018-09-22 2021-11-11 Novaliq Gmbh Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
CA3112504A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
MY206642A (en) 2018-10-12 2024-12-30 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US20220008397A1 (en) * 2019-01-21 2022-01-13 Novaliq Gmbh Pharmaceutical composition for the treatment of ocular neovascularisation
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
US20220226426A1 (en) 2019-05-24 2022-07-21 Novaliq Gmbh Ophthalmic composition for the treatment of ocular allergy
AU2020340561A1 (en) 2019-09-06 2022-03-31 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
WO2021048803A1 (en) 2019-09-13 2021-03-18 Minas Coroneo Eye drop dispenser
WO2021191273A1 (en) 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
CN120916776A (zh) * 2023-02-13 2025-11-07 诺瓦利克有限责任公司 用于眼表疾病患者的眼部手术准备的眼用组合物
AU2023270196B2 (en) * 2023-11-20 2025-06-26 Dyer, Gordon Wayne DR Method of Arthropod Egress

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
ATE109970T1 (de) 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE19861012A1 (de) * 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
CA2372448A1 (en) * 1999-04-30 2000-11-09 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
DE19938668B4 (de) * 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
CA2563544A1 (en) * 2004-04-19 2005-10-27 Centre National De La Recherche Scientifique (C.N.R.S.) Lung surfactant supplements
JP2008501806A (ja) * 2004-06-08 2008-01-24 オキュラリス ファーマ， インコーポレイテッド 疎水性眼用組成物および使用方法
DE102007055046A1 (de) * 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
PL2110126T3 (pl) 2008-04-18 2012-04-30 Novaliq Gmbh Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej

Also Published As

Publication number Publication date
CA2941956A1 (en) 2011-06-23
EP2512515A1 (en) 2012-10-24
KR20120115977A (ko) 2012-10-19
AU2010333039B2 (en) 2014-08-28
US20120244177A1 (en) 2012-09-27
KR101722039B1 (ko) 2017-03-31
JP6731039B2 (ja) 2020-07-29
EP2335735A1 (en) 2011-06-22
IN2012DN03128A (es) 2015-09-18
HK1172269A1 (en) 2013-04-19
BR122020020872B1 (pt) 2021-09-08
BR122017018955B1 (pt) 2022-03-08
US8614178B2 (en) 2013-12-24
CA2776860C (en) 2016-10-25
CA2776860A1 (en) 2011-06-23
JP2019006803A (ja) 2019-01-17
JP2017078086A (ja) 2017-04-27
DK2512515T3 (en) 2014-03-10
ES2449308T3 (es) 2014-03-19
CA2941956C (en) 2018-09-04
CN102652022B (zh) 2014-12-17
JP6096731B2 (ja) 2017-03-15
WO2011073134A1 (en) 2011-06-23
EP2512515B1 (en) 2013-12-25
JP2015028064A (ja) 2015-02-12
JP2019070003A (ja) 2019-05-09
PL2512515T3 (pl) 2014-05-30
KR20160105533A (ko) 2016-09-06
KR101652714B1 (ko) 2016-09-01
BR112012014190A2 (pt) 2016-05-31
JP6397472B2 (ja) 2018-09-26
AU2010333039A1 (en) 2012-07-12
JP2013513586A (ja) 2013-04-22
PT2512515E (pt) 2014-03-04
JP5663595B2 (ja) 2015-02-04
BR112012014190B1 (pt) 2021-03-02
CN102652022A (zh) 2012-08-29
BR112012014190B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
MX2012006720A (es) Composicion farmceutica para el tratamiento de sindrome del ojo seco.
MX389597B (es) Inhibidores de cdk2/4/6 de piridopirimidinona.
EP4342540A3 (en) Substituted heterocyclyl derivatives as cdk inhibitors
WO2014047427A3 (en) Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
MX363182B (es) Composiciones que comprenden mezclas de alcanos semifluorados.
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
AR065721A1 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa. composiciones farmaceuticas.
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
WO2014028931A3 (en) Compounds and methods for treating mammalian gastrointestinal microbial infections
BR112012007332A2 (pt) nova composição farmacêutica que compreende um macrólido imunossupressor
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
EP4414376A3 (en) Novel depsipeptide and uses thereof
EP3216798A3 (en) Ketolide compounds
MX341220B (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas.
CL2012003521A1 (es) Derivado piperidino (r)-n-((r)-1-((3s-4s)-4-(4-clorofenil)-3,4-dihidroxi-3-metilpiperidin-1-il)-3-metil-1-oxobutan-2-il)-3,3-difluorociclopentanocarboxamida, modulador receptor quimiocinas; composicion farmaceutica; y uso del compuesto y su composicion en enfermedades inflamatorias y autoinmunitarias, entre otras.
BR112017009510A2 (pt) composições compreendendo ciclosporina
WO2015150449A3 (en) Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2
BRPI0913297B8 (pt) composição farmacêutica estabilizada
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
NZ755637A (en) Compounds and their use in the treatment of schistosomiasis
PH12017502426A1 (en) Solid pharmaceutical compositions for treating hcv
WO2011046905A3 (en) Pharmaceutical compositions
PH12018500132A1 (en) Solid pharmaceutical compositions for treating hcv

Legal Events

Date Code Title Description
FG Grant or registration